Research programme: autologous stem cell therapies - BrainStorm Cell Therapeutics

Drug Profile

Research programme: autologous stem cell therapies - BrainStorm Cell Therapeutics

Alternative Names: NurOwn™ program two

Latest Information Update: 03 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Glial cell line-derived neurotrophic factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 30 Nov 2015 BrainStorm Cell Therapeutics receives $US7 35 000 grant from Israel's Office of the Chief Scientist (OCS) in the Ministry of Economy for NurOwn™ development in Neurodegenerative disorders
  • 02 Sep 2014 Early research in Neurodegenerative disorders in Israel is ongoing (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top